Patients with DMD exhibit dysregulated glycolytic metabolism with a reduction in phosphoglycerate mutase (PYGM), aldolase A (ALDOA), cytoplasmic glycerol-3-phosphate dehydrogenase (GPD1), triosephosphate isomerase (TPI1), phosphoglycerate kinase (PGK1), beta enolase (ENO3), and pyruvate kinase M1/M2 (PKM2) enzymes [111]. The gene discussed is ENO3; the disease is Duchenne muscular dystrophy.